Tags: layoffs, Genentech, restructuring

Genentech Restructuring: 143 Positions Cut in Latest Round

By FieldPulse Editorial · May 21, 2026

A restructuring story for Roche/Genentech reps tracking layoffs, resource shifts, and what portfolio concentration could mean for field support.

Genentech has announced a new round of layoffs affecting 143 employees , marking a continuation of the restructuring efforts that began earlier this year.

This latest move follows a series of spring reductions as the company realigns its commercial and R&D operations to focus on high-growth therapeutic areas.

Strategic Realignment The cuts are reportedly part of a broader strategy to streamline Genentech's portfolio and reduce overhead in legacy segments.

While the company remains a powerhouse in oncology and immunology, the pressure from biosimilars and shifting market dynamics has necessitated a leaner organizational structure.

Impact on the Field While the specific breakdown of roles has not been fully disclosed, insiders suggest that both corporate and field-based positions are included in this wave.

For reps on the ground, this signals a tightening of resources and a potential shift in territory management as the company prioritizes its launch pipeline over mature brands.

What's Next? Genentech has emphasized that these changes are necessary to ensure long-term sustainability and to fuel investment in next-generation therapies.

However, for the affected staff, the news adds to a growing sense of uncertainty across the biopharma landscape in 2026.